KYMR Kymera Therapeutics (KYMR) Q1 FY26 earnings call
Kymera Therapeutics marked its 10-year anniversary by highlighting significant pipeline progress and a strong financial foundation. The company is focused on advancing its wholly-owned programs, KT-621 and KT-579, through key clinical milestones, while also seeing its partnered programs, KT-200 with Gilead and KT-485 with Sanofi, move forward. Management emphasized its commitment to becoming a fully integrated global commercial company, leveraging its unique capabilities in targeted protein degradation to address high-value disease targets.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.